4D
4DX.AU 4DMEDICAL Ltd
- Market cap
- AUD 1.47B
- P/E
- -
- P/B
- 8.64x
- ROE
- -120.1%
- Dividend yield
- -
- Fundamental score
- 1.6/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is 4DX.AU undervalued?
Graham numberThe Graham number of 4DMEDICAL Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
4DMEDICAL Ltd fundamental analysis
6 of 21 checks passedROE 0/2
Low return on equity (-120.1%), below 10%.
ROA 0/1
Return on assets (-56.0%) is below the industry median (-35.3%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-429.7%) is below the industry median (24.9%).
Revenue Growth 2/2
Revenue grew 114.2% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (1.9%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Cash Runway 2/2
Cash covers 8.6 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (8.6x) is above the industry median (4.0x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
4DMEDICAL Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About 4DMEDICAL Ltd
4DMedical Limited operates as a medical technology company in the United States and Australia. The company engages in medical research technology and development of a non invasive respiratory imaging solution. It offers CT:VQ, non-contrast post processing technology; CAC, a non-contrast cardiothoracic risk assessment sotware; CT LVAS, a regional lung function imaging software; IQ-UIP, a state-of-the-art software; LDAf, Patented Parametric Response Mapping (PRM) technology; L…
Full company profile4DMEDICAL Ltd financial statements
4DMEDICAL Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 1.93K | 789K | 695K | 1.23M | 217K | 1.05M | 719K | 3.75M | 5.85M | 7.06M |
| Gross Profit | -2.93M | -3.01M | -3.73M | -8.13M | 125K | 281K | 684K | 3.52M | 5.39M | 6.62M |
| Operating Income | -4.68M | -5.17M | -7.02M | -16.0M | -13.7M | -36.8M | -30.7M | -28.0M | -47.5M | -57.5M |
| EBITDA | -4.55M | -4.35M | -6.74M | -14.2M | -18.0M | -35.3M | -33.7M | -31.9M | -42.8M | -52.0M |
| Net Income | -3.97M | -3.94M | -6.49M | -22.0M | -21.4M | -24.6M | -31.5M | -36.0M | -30.1M | -204M |
| EPS | -0.03 | -0.03 | -0.04 | -0.08 | -0.08 | -0.08 | -0.10 | -0.09 | -0.06 | -0.34 |
| Balance Sheet | ||||||||||
| Total Assets | 4.95M | 5.45M | 9.02M | 15.8M | 92.6M | 74.3M | 92.9M | 120M | 94.8M | 365M |
| Total Liabilities | 1.70M | 1.67M | 4.47M | 27.6M | 9.28M | 14.8M | 21.5M | 49.1M | 30.6M | 195M |
| Shareholders' Equity | 3.25M | 3.78M | 4.56M | -11.8M | 83.4M | 59.5M | 71.5M | 70.9M | 64.2M | 170M |
| Cash & Short-term Investments | 1.15M | 1.66M | 3.09M | 8.43M | 80.9M | 51.1M | 69.6M | 30.6M | 6.88M | 278M |
| Total Debt | - | 1.00M | 3.00M | 16.9M | 1.69M | 6.24M | 5.14M | 5.12M | 4.31M | 3.22M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -2.16M | -3.38M | -5.78M | -7.65M | -14.5M | -25.3M | -22.7M | -30.9M | -34.5M | -31.3M |
| Capital Expenditure | 1.13M | 1.43M | 1.28M | 1.16M | 725K | 3.08M | 731K | 303K | 85.8K | 950K |
| Free Cash Flow | -3.29M | -4.81M | -7.06M | -8.81M | -15.2M | -28.3M | -23.4M | -31.2M | -34.6M | -32.2M |
| Ratios | ||||||||||
| ROE | -122.3% | -104.2% | -142.5% | - | -25.7% | -41.3% | -44.0% | -50.7% | -46.8% | -120.1% |
| ROA | -80.3% | -72.2% | -71.9% | -138.9% | -23.1% | -33.1% | -33.9% | -30.0% | -31.7% | -56.0% |
| Net Profit Margin | -206,438.3% | -498.8% | -934.0% | -1,783.0% | -9,872.2% | -2,332.6% | -4,378.0% | -958.3% | -513.7% | -2,895.1% |
| Debt to Equity | - | 0.26x | 0.66x | - | 0.02x | 0.10x | 0.07x | 0.07x | 0.07x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
4DMEDICAL Ltd dividends
4DMEDICAL Ltd has not paid dividends in the last 10 fiscal years.
Who owns 4DMEDICAL Ltd
- Insiders 16.48%
- Institutions 23.92%
- Public & others 59.61%
- Shares outstanding 602M
- Free float 498M
4DMEDICAL Ltd company profile
- Company name
- 4DMEDICAL Ltd
- Ticker
- 4DX.AU
- ISIN
- AU0000095416
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 181
- Fiscal year end
- June
- Address
- Melbourne Connect, Carlton, VIC, Australia, 3053
- Phone
- 61 3 9545 5940
- Website
- 4dmedical.com
About 4DMEDICAL Ltd
4DMedical Limited operates as a medical technology company in the United States and Australia. The company engages in medical research technology and development of a non invasive respiratory imaging solution. It offers CT:VQ, non-contrast post processing technology; CAC, a non-contrast cardiothoracic risk assessment sotware; CT LVAS, a regional lung function imaging software; IQ-UIP, a state-of-the-art software; LDAf, Patented Parametric Response Mapping (PRM) technology; LDAi, an automated detection of potential emphysema software; LTA provides visualization and quantification of the lung textures; PHA Analysis, a cutting-edge, fully-automated imaging solution; XV LVAS, a lung airflow imaging software; and XV Scanner, a lung function scanner. The company has partnership with AstraZeneca to launch and expand a lung health screening program; and a contractual engagement with GlaxoSmithKline to provide its proprietary quantitative lung imaging analytics in support of pulmonary drug development and clinical research. 4DMedical Limited was incorporated in 2012 and is based in Carlton, Australia.
4DMEDICAL Ltd management
1- Mr. Matt TuckerChief Commercial Officer